GUTS: New Study Shows Revita Maintains Weight Loss After GLP-1 Drug Discontinuation
Revita’s Early Trial Results Highlight Significant Gap in Obesity Treatment
For anyone following obesity therapies, the big question is: what happens after patients stop GLP-1 drugs? According to newly released interim results from Fractyl Health’s REMAIN-1 study, there may now be a compelling answer. The company’s investigational procedure, Revita, demonstrated that patients continued to lose weight after coming off GLP-1 medication, in stark contrast to control patients who rapidly regained weight.
Statistically Significant Outcomes Point to a Potential New Category
The REMAIN-1 Midpoint Cohort randomized adults with obesity (who had already lost at least 15% body weight on tirzepatide) to either the Revita endoscopic procedure or a sham procedure. Three months after GLP-1 discontinuation, the Revita group achieved an additional 2.5% reduction in total body weight, while the sham group gained back 10%. This difference reached statistical significance (p=0.014) and suggests a possible new solution for durable, drug-free weight maintenance.
| Group | Body Weight Change (3 Months After GLP-1 Discontinuation) | Number of Patients |
|---|---|---|
| Revita | -2.5% | 29 |
| Sham | +10.0% | 16 |
Safety Profile Remains Consistent with Earlier Revita Trials
No serious or Grade II+ adverse events related to Revita were observed in this cohort. Side effects reported were mild and temporary, adding to the evidence that Revita is a safe approach based on results from earlier studies.
Upcoming Milestones to Watch: 6-Month Data on the Horizon
The REMAIN-1 trial continues, with 6-month randomized data expected in the first quarter of 2026. The pivotal cohort, designed to validate and extend these results, has completed enrollment, with primary endpoint data expected later next year and a possible PMA filing planned for the second half of 2026.
Implications: Revita Could Reshape the Future of Obesity Care
The gap in obesity treatment—maintaining weight loss after GLP-1 discontinuation—remains a significant clinical challenge. Revita’s trial results signal the potential emergence of a new therapeutic option focused on long-term weight maintenance without the need for chronic medication. If these early results hold, Fractyl Health’s approach could redefine how the medical community addresses obesity relapse and maintenance.
Key Details at a Glance
| Key Metric | Value |
|---|---|
| Study Cohort | REMAIN-1 Midpoint (N=45) |
| Statistical Significance | p=0.014 |
| Next Milestone | 6-month data (Q1 2026) |
| Potential PMA Filing | H2 2026 |
For investors and industry watchers, the months ahead will reveal whether Revita’s promising effect in sustaining weight loss post-GLP-1 will persist in larger patient groups and over a longer period. Fractyl Health will provide more detail during its webcast event today at 8:00 a.m. ET, with the replay available online.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI